To determine the incremental cost-effectiveness of prophylactic percutaneous transluminal angioplasty with stent placement (PTA-S) in patients with incidentally discovered, asymptomatic renal artery stenosis (RAS) compared to delaying PTA-S until patients develop refractory hypertension or renal insufficiency (therapeutic PTA-S).
Methods:
The Markov decision analysis model was used to determine the incremental cost per quality adjusted life year (QALY) saved for prophylactic PTA-S as compared to therapeutic PTA-S in a hypothetical cohort of patients with 50% unilateral atherosclerotic RAS followed from age 61 to death.
Results:
Prophylactic PTA-S compared to therapeutic PTA-S results in more QALYs/patient (10.9 versus 10.3) at higher lifetime costs ($23,664 versus $16,558). The incremental cost effectiveness of prophylactic PTA-S was estimated to be $12,466/QALY. Prophylactic stenting was not cost effective (>$50,000/QALY) if the modeled incidence of stent restenosis exceeded 15%/year and the incidence of progression in the contralateral renal artery was <2% of arteries/year.
Conclusions:
PTA-S of incidental, asymptomatic unilateral RAS may improve patients' quality of life at an acceptable incremental cost. However, this technology should be used hesitantly until a randomized comparison confirms its effectiveness.
SchwartzCJWhiteTA. Stenosis of renal artery: An unselected necropsy study. BMJ. 1964; 2: 1415–1421.
2.
HardingMBSmithLRHimmelsteinSI. Renal artery stenosis: Prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol.1992; 2: 1608–1616.
3.
ZierlerREBergelinROIsaacsonJA. Natural history of atherosclerotic renal artery stenosis: A prospective study with duplex ultrasonography. J Vasc Surg.1994; 19: 250–257.
4.
BaboolalKEvansCMooreRH. Incidence of end-stage renal disease in medically treated patients with severe bilateral atherosclerotic renovascular disease. Am J Kidney Dis.1998; 31: 971–977.
5.
BurketMWCooperCJKennedyDJ. Renal artery angioplasty and PTA-S: Predictors of a favorable outcome. Am Heart J.2000; 139: 64–71.
6.
van JaarsveldBCKrijnenPPietermanH. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. N Engl J Med.2000; 342: 1007–1014.
7.
NovickAC. Options for therapy of ischemic nephropathy: Role of angioplasty and surgery. Semin Nephol.1996; 16: 53–60.
8.
1995 update of the working group reports on chronic renal failure and renovascular hypertension. National High Blood Pressure Education Program Working Group. Arch Intern Med.1996; 156: 1938–1947.
9.
LeertouwerTCGussenhovenEJBoschJL. PTA-S for renal arterial stenosis: Where do we stand? A meta-analysis. Radiology. 2000; 216: 78–85.
10.
WhiteCJ. Open renal arteries are better than closed renal arteries. Cathet Cardiovasc Diagn.1998; 45: 9–10.
11.
ChabovaVSchirgerAStansonAW. Outcomes of atherosclerotic renal artery stenosis managed with revascularization. Mayo Clin Proc.2000; 75: 437–444.
12.
SonnenbergFABeckJR. Markov models in medical decision making: A practical guide. Med Decis Making. 1993; 13: 322–338.
13.
CrowleyJJSantosRMPeterRH. Progression of renal artery stenosis in patients undergoing cardiac catheterization. Am Heart J.1998; 136: 913–918.
14.
CapsMTPerissinottoCZierlerRE. Prospective study of atherosclerotic disease progression in the renal artery. Circulation. 1998; 98: 2866–2872.
15.
ConlonPJAthirakulKKovalikE. Survival in renal vascular disease. J Am Soc Nephrol.1998; 9: 252–256.
16.
MaillouxLUNapolitanoBBellucciAG. Renal vascular disease causing end-stage renal disease, incidence, clinical correlates, and outcomes: A 20-year clinical experience. Am J Kidney Dis.1994; 24: 622–629.
17.
PernegerTVKlagMJFeldmanHI. Projections of hypertension-related renal disease in middle-aged residents of the United States. JAMA. 1993; 269: 1272–1277.
18.
PernegerTVNietoFJWheltonPK. A prospective study of blood pressure and serum creatinine. Results from the ‘Clue’ Study and the ARIC Study. JAMA. 1993; 269: 488–493.
19.
VolkMStrotzerMLenhartM. Time-resolved contrast-enhanced MR angiography of renal artery stenosis: Diagnostic accuracy and intraobserver variability. AJR Am J Roentgeol.2000; 174: 1583–1588.
20.
ChaikofELSmithRBSalamAA. Empirical reconstruction of the renal artery: Long-term outcome. J Vasc Surg.1996; 24: 406–414.
21.
United States Life Tables, 1997. Washington, DC: National Center for Health Statistics. 1999. National Vital Statistics Reports, Vol, 47, No. 28.
22.
HanssonLZanchettiACarruthersSG. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet. 1998; 351: 1755–1762.
23.
CambriaRPBrewsterDCL'ItalienGJ. Renal artery reconstruction for the preservation of renal function. J Vasc Surg.1996; 24: 371–382.
24.
DeanRHKruegerTCWhiteneckJM. Operative management of renovascular hypertension. Results after a follow-up of fifteen to twenty-three years. J Vasc Surg.1984; 1: 234–242.
25.
van RoodenCJvan BockelJHDe BackerGG. Long-term outcome of surgical revascularization in ischemic nephropathy: Normalization of average decline in renal function. J Vasc Surg.1999; 29: 1037–1049.
26.
BlumUKrummeBFlugelP. Treatment of ostial renal-artery stenoses with vascular endoprostheses after unsuccessful balloon angioplasty. N Engl J Med.1997; 336: 459–465.
27.
HardenPNMacLeodMJRodgerRS. Effect of renal-artery stenting on progression of renovascular renal failure. Lancet. 1997; 349: 1133–1136.
28.
AcherCWBelzerOFGristTM. Late renal function in patients undergoing renal revascularization for control of hypertension and/or renal preservation. Cardiovasc Surg.1996; 4: 602–606.
29.
RamseySDNeilNSullivanSD. An economic evaluation of JNC Hypertension Guidelines using data for a randomized controlled trial. J Am Board Fam Pract.1999; 12: 105–114.
30.
BrunsFJSeddonPSaulM. The cost of caring for end stage kidney disease patients: An analysis based on hospital financial transaction records. J Am Soc Nephrol.1998; 9: 884–890.
31.
LibscombJWeinsteinMCTorranceGW. Time preference. In: GoldMRSiegelJFRusssellLB, eds. Cost Effectiveness in Health and Medicine. New York: Oxford University Press; 1996: 214–246.
32.
KiberdBAJindalKK. Screening to prevent renal failure in insulin dependant diabetic patients: An economic evaluation. BMJ. 1995; 311: 1595–1599.
33.
DorrosGJaffMMathiakL. Four-year follow-up of Palmaz stent revascularization as treatment for atherosclerotic renal artery stenosis. Circulation. 1998; 98: 642–647.
34.
WeibullHBergqvistDBergentzSE. Clinical outcome and health care costs in renal revascularization—percutaneous transluminal renal angioplasty versus reconstructive surgery. Brit J Surg.1991; 78: 620–624.
35.
van de VenPJKaateeRBeutlerJJ. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: A randomized trial. Lancet. 1999; 353: 282–286.
